Overview
Nawaloka Hospitals is a private healthcare provider offering hospital care, diagnostics, laboratories and specialist clinical services in Sri Lanka, alongside digital health and international patient services.
The latest quarter showed stronger operating activity, but that improvement did not reach shareholders. Finance costs, tax, associates and foreign-exchange effects absorbed most of operating profit, leaving the company's recovery uneven.
Price performance
The share fell 14.8% over three months to LKR 13.80 as at 2026-08-14, underperforming the ASPI's 5.6% decline. Over one year it gained 112.3%, well ahead of the index's 9.3% return, so the longer-term gain masks a clear recent reversal.
The price stood at 70.5% of its 52-week range, below its high but well above its low. Recent volatility has run below the company's own one-year level, while trading volume has also been below its recent norm, indicating quieter price activity rather than a proven change in direction.
Valuation
Nawaloka trades at a P/E of 14.85 and a P/B of 3.21, against healthcare-sector medians of 11.43 and 1.52 respectively. With annual ROE at only 1.1%, the premium book valuation is not supported by strong current returns on owners' capital.
The reported dividend yield is 0.0%. Dividend history is not supplied, so the direction of the payout cannot be assessed; no sector percentile is provided for the valuation measures.
News and sentiment
Coverage is thin: one material company article was recorded in the last 90 days, with one positive, no negative and no neutral articles.
No company news appeared in the last 30 days, and no confirmed or undated corporate actions are listed.
Financials
For the quarter ended 2026-06-30, revenue grew 19.4% year-on-year and operating profit grew 26.5%, while net profit fell 90.3%. Gross margin widened to 56.4% from 53.7%, and operating margin rose to 14.5% from 13.7%; the June gross margin ranked 2nd of 8 comparable June quarters and operating margin ranked 4th of 8.
Net margin dropped to 2.0% from 24.8%, ranking 5th of 8 comparable June quarters. Operating profit was LKR 511 million, but net profit was only LKR 71 million because the below-line drag was LKR 440 million, versus a LKR 330 million benefit in the year-ago quarter.
Owners' equity was LKR 6.06 billion at the latest quarter-end, down from LKR 6.36 billion a year earlier, while the share count remained 1.41 billion across the supplied periods. These figures are historical through 2026-06-30; no later company results are included.
Risks
The most material risk is financial flexibility. At 31 March 2025, debt was 136.0% of owners' equity, interest cover was only 1.09 times and the current ratio was 0.32, leaving limited room for weaker operating conditions or renewed finance-cost pressure.
Annual cash conversion was 1.12 times at that date, so the audited year's operating profit was cash-backed, but this does not offset the latest quarter's sharp below-line squeeze. Healthcare operators also face sector-wide exposure to disruptive cybersecurity incidents, while the wider backdrop includes elevated inflation after higher fuel prices.
Outlook
As at 2026-08-15, the next specific event is the group's filing for the quarter ending 2026-09-30, scheduled within the exchange's historical range of 2026-11-07 to 2027-01-07. That filing will show whether the latest gap between operating profit and net profit was temporary or persisted.
Lower Treasury bill and bond yields in the wider market could reduce financing pressure, but the supplied data cannot establish how quickly that would affect Nawaloka. Sector proposals on pharmaceutical manufacturing remain proposal-led, with no reported implementation or operating results, so they do not yet change the company's earnings evidence.